Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lundbeck

45.26 DKK+3.71 %25.9, 16.59
Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+3.71 %
+8.96 %
+5.60 %
+20.24 %
+4.87 %
-0.79 %
+19.93 %
+29.06 %
+83.98 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Read more
Market cap
45.07B DKK
Turnover
40.17M DKK
Revenue
24.63B
EBIT %
21.42 %
P/E
14.06
Dividend yield-%
2.54 %
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 04.09.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.11
2026

Interim report Q3'26

10.2
2027

Annual report '26

Analyst Comment25.09.2026, 09.04 by
Rasmus Køjborg, Michael Friis

Today's equity news 25/09/2026: Lundbeck, Sampo, and North Media

Today's equity news 09/25/2026: Lundbeck, Sampo and North Media

LundbeckSampoNorth Media
Press release25.09.2026, 08.00

H. Lundbeck A/S: Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters

Lundbeck
Regulatory press release21.09.2026, 16.20

Correction - Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release17.09.2026, 08.53

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck
Dagens aktienyheder 16/09/2026: Hafnia, Torm, Lundbeck og Scandinavian Medical Solutions
Analyst Comment16.09.2026, 08.50 by
Victor Skriver

Dagens aktienyheder 16/09/2026: Hafnia, Torm, Lundbeck og Scandinavian Medical Solutions

Dagens aktienyheder 16/09/2026: Hafnia, Torm, Lundbeck og Scandinavian Medical Solutions

TormHafniaLundbeckScandinavian Medical Solutions
Press release16.09.2026, 08.00

H. Lundbeck A/S: Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

Lundbeck
Press release15.09.2026, 09.00

H. Lundbeck A/S: Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Lundbeck
Dagens aktienyheder 14/09/2026: Lundbeck og Danish Aerospace and Defence Company
Analyst Comment14.09.2026, 08.54 by
Victor Skriver

Dagens aktienyheder 14/09/2026: Lundbeck og Danish Aerospace and Defence Company

Dagens aktienyheder 14/09/2026: Lundbeck og Danish Aerospace and Defence Company

LundbeckDanish Aerospace and Defence Company
Press release11.09.2026, 10.00

H. Lundbeck A/S: The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

Lundbeck
HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport
Video10.09.2026, 10.55 by
Michael Friis, Nikolaj Pedersen

HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport

Europæiske futures indikerer en begrænset positiv åbning efter gårsdagens nedtur, forud for fredagens afgørende inflationsrapport. Herhjemme fokus på blandt andet Mærsk, Novo, NTG, B&O.

Bang & OlufsenLundbeckNovo NordiskDSVA.P. Møller - MærskNTG Nordic Transport Group
HCA Morgenbørs 08/09 - Napatech i fokus i interview med Anders Knudsen og stigende oliepriser
Video08.09.2026, 09.48 by
Jacob Frehr, Michael Friis

HCA Morgenbørs 08/09 - Napatech i fokus i interview med Anders Knudsen og stigende oliepriser

Udsigt til faldende aktiemarkeder fra morgenstunden i Europa på stigende oliepriser. Gæst i studiet her til morgen er Anders Knudsen, hvor vi sætter fokus på casen i Napatech.

NapatechZealand PharmaLundbeckNetcompany GroupGenmabISSNovo NordiskTorm
Dagens aktienyheder 07/09/2026: Lundbeck, Hafnia og ExpreS2ion Biotech
Analyst Comment07.09.2026, 08.49 by
Victor Skriver

Dagens aktienyheder 07/09/2026: Lundbeck, Hafnia og ExpreS2ion Biotech

Dagens aktienyheder 07/09/2026: Lundbeck, Hafnia og ExpreS2ion Biotech

LundbeckHafniaExpreS2ion Biotech
Lundbeck (Investeringscase): Stærkt H1 2026 med vækst, nedgearing og fremrykkede katalysatorer
Research04.09.2026, 14.15 by
Michael Friis, Victor Skriver

Lundbeck (Investeringscase): Stærkt H1 2026 med vækst, nedgearing og fremrykkede katalysatorer

I forbindelse med Lundbecks H1 2026-regnskab har vi opdateret vores investeringscase. Den afspejler nu den fastholdte 2026 guidance, en pipeline hvor de væsentligste katalysatorer er rykket frem i tid, og en yderligere opjustering af konsensus' pipelinebidrag efter 2030.

Lundbeck
HCA Morgenbørs 03/09 - Jakob Have interview og stilstand i oliepris og renter
Video03.09.2026, 11.09 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 03/09 - Jakob Have interview og stilstand i oliepris og renter

Markederne kæmper med at finde retning trods stilstand i oliepris og renter. Herhjemme fokus på analytikerændringer og nyheder. Gæst i studiet her til morgen er Jakob Have fra Nordic Compound Invest.

Donkey RepublicNetcompany GroupChemoMetecGomSpacePandoraLundbeckNNITSkjern Bank
Press release03.09.2026, 09.00

H. Lundbeck A/S: Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

Lundbeck
Press release24.08.2026, 09.00

H. Lundbeck A/S: European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Lundbeck
Analyst Comment21.08.2026, 13.53 by
Victor Skriver

Lundbeck: Præsentation af delårsrapport for H1 2026 (optagelse)

I dag præsenterede Jens Høyer, Vice President & Head of Investor Relations, selskabets resultater for H1 2026 og besvarede spørgsmål fra publikum ved et live online-event.

Lundbeck
Lundbeck – Præsentation af delårsrapport for H1 2026
Webcast21.08.2026, 11.00

Lundbeck – Præsentation af delårsrapport for H1 2026

H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for H1 2026 den 19. august 2026. Den 21. august kl. 11.00 vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.

Lundbeck
Mød ledelsen i Ascelia Pharma, Lundbeck, SP Group, WindowMaster og North Media og stil dine spørgsmål til dagens investorpræsentationer
Analyst Comment21.08.2026, 08.30 by
Victor Skriver

Mød ledelsen i Ascelia Pharma, Lundbeck, SP Group, WindowMaster og North Media og stil dine spørgsmål til dagens investorpræsentationer

I dag afholder vi fem online investorevents. Kl. 10:00 præsenterer Ascelia Pharma CEO Magnus Corfitzen resultaterne for Q2 2026. Kl. 11:00 præsenterer Lundbeck Jens Høyer, Vice President & Head of Investor Relations, halvårsrapporten for H1 2026. Kl. 12:00 præsenterer SP Group CEO Lars Bering og CFO Allan Jeppesen regnskabet for 2. kvartal 2026. Kl. 13:00 præsenterer WindowMaster CEO Erik Boyter og CFO Steen Overgaard Sørensen halvårsrapporten for H1 2026. Kl. 14:00 gennemgår North Medias ledelse regnskabet for 2. kvartal 2026. Tilmeld dig og stil dine spørgsmål allerede nu.

SP GroupAscelia PharmaLundbeckWindowMaster InternationalNorth Media
HCA Morgenbørs 19/08 - Royal Unibrew CEO-interview og regnskaber i fokus
Video19.08.2026, 10.53 by
Rasmus Køjborg, Jacob Frehr

HCA Morgenbørs 19/08 - Royal Unibrew CEO-interview og regnskaber i fokus

Udsigt til negativ åbning i Europa efter større fald i Asien og USA. Fokus på regnskabsaktuelle Carlsberg, FLS, Jyske Bank, Lundbeck m.fl. Gæst i studiet her til morgen er CEO Lars Jensen fra Royal Unibrew.

Royal UnibrewColoplastDFDSCopenhagen CapitalLundbeckFLSmidth & Co.CarlsbergJyske BankRockwoolBar DjusColumbusGrønlandsbankenNorth Media